← Browse by Condition
Medical Condition

hematologic neoplasms

Total Trials
4
Recruiting Now
4
Trial Phases
Phase 3, Phase 1

ClinicalMetric tracks all active clinical trials for hematologic neoplasms sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — hematologic neoplasms Clinical Trials

How many clinical trials are currently recruiting for hematologic neoplasms?
ClinicalMetric currently tracks 4 actively recruiting clinical trials for hematologic neoplasms, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 4. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for hematologic neoplasms?
hematologic neoplasms research spans Phase 1 (2 trials), Phase 3 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a hematologic neoplasms clinical trial?
Eligibility criteria for hematologic neoplasms trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
2
Phase 3
1
Top Sponsors
Asan Medical Center 1 trial
National Cancer Institute (NCI) 1 trial
Instituto Nacional de Cancerologia de Mexico 1 trial
Janssen Research & Development, LLC 1 trial

Recruiting Clinical Trials

NCT07485855 Phase 3
Recruiting

Influenza Vaccination Strategy for Patients With Hematologic Malignancy

Enrollment
60 pts
Location
South Korea
Sponsor
Asan Medical Center
View Trial →
NCT07162038 Phase 1
Recruiting

Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide-Based HLA-Haploidentical Hematopoietic Cell Transplantation

Enrollment
155 pts
Location
United States
Sponsor
National Cancer Institute (NCI...
View Trial →
NCT06422533
Recruiting

Ceftolozane/Tazobactam vs. Piperacillin/Tazobactam for the Treatment of Bacteremia in Hemato-oncological Patients

Enrollment
226 pts
Location
Mexico
Sponsor
Instituto Nacional de Cancerol...
View Trial →
NCT07572006 Phase 1
Recruiting

A Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies

Enrollment
280 pts
Location
United States
Sponsor
Janssen Research & Development...
View Trial →
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology